{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:38:27Z","timestamp":1794008307629,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cyto.2025.156921","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T01:15:27Z","timestamp":1743124527000},"page":"156921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Aqueous humor mediator levels as biomarkers of anti-VEGF response in age-related macular degeneration"],"prefix":"10.1016","volume":"190","author":[{"given":"St\u00e9phanie","family":"Baillif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Nahon-Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Pace-Loscos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Dufies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.156921_bb0005","doi-asserted-by":"crossref","first-page":"1753e1763","DOI":"10.1016\/j.ophtha.2017.05.035","article-title":"Prevalence of age-related macular degeneration in Europe: the past and the future","volume":"124","author":"Colijn","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cyto.2025.156921_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100114","article-title":"Incidence and prevalence of neovascular age-related macular degeneration in France between 2008 and 2018. The LANDSCAPE study","volume":"2","author":"Creuzot-Garcher","year":"2022","journal-title":"Ophthalmol. Sci."},{"issue":"1","key":"10.1016\/j.cyto.2025.156921_bb0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2021","journal-title":"Genes Dis."},{"key":"10.1016\/j.cyto.2025.156921_bb0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0025","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGFA trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cyto.2025.156921_bb0030","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cyto.2025.156921_bb0035","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.cyto.2025.156921_bb0040","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/s41598-018-19594-6","article-title":"Intraocular inflammatory cytokines in patients with neovascular age-related macular degeneration before and after initiation of intravitreal injection of anti-VEHG inhibitor","volume":"8","author":"Sato","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.156921_bb0045","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/aos.12770","article-title":"Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration","volume":"93","author":"Fauser","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0050","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/IAE.0000000000000157","article-title":"Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection","volume":"34","author":"Agawa","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.cyto.2025.156921_bb0055","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/archophthalmol.2010.227","article-title":"Monocyte chemo-attractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration","volume":"128","author":"Jonas","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0060","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ophtha.2009.05.039","article-title":"Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab","volume":"116","author":"Funk","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cyto.2025.156921_bb0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000478705","article-title":"Dynamics of inflammatory factors in aqueous humor during ranibizumab or aflibercept treatment for age-related macular degeneration","volume":"58","author":"Motohashi","year":"2017","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.cyto.2025.156921_bb0070","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/IAE.0b013e318195cb15","article-title":"Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment","volume":"29","author":"Roh","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.cyto.2025.156921_bb0075","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1167\/iovs.16-19772","article-title":"The intraocular cytokine profile and therapeutic response in persistent neovascular age-related macular degeneration","volume":"57","author":"Rezar-Dreindl","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cyto.2025.156921_bb0080","first-page":"721","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye(London)"},{"key":"10.1016\/j.cyto.2025.156921_bb0085","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/IAE.0b013e3181e7976b","article-title":"Do we need a new classification for choroidal neovascularization in age-related macular degeneration?","volume":"30","author":"Freund","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.cyto.2025.156921_bb0090","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting Neovascular age-related macular degeneration data: consensus on Neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cyto.2025.156921_bb0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12950-018-0203-x","article-title":"Dynamics of soluble vascular endothelial growth factor receptors and their ligands in aqueous humour during ranibizumab for age-related macular degeneration","volume":"15","author":"Motohashi","year":"2018","journal-title":"J. Inflamm. (London)"},{"key":"10.1016\/j.cyto.2025.156921_bb0100","article-title":"Comparison of intraocular cytokine levels of choroidal neovascularization secondary to different retinopathies","volume":"8","author":"Liu","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.cyto.2025.156921_bb0105","first-page":"298","article-title":"Aqueous humor levels of vascular endothelial growth factor and stromal cell-derived factor-1\u03b1 in age-related macular degeneration","volume":"6","author":"Keles","year":"2021","journal-title":"Beyoglu Eye J."},{"key":"10.1016\/j.cyto.2025.156921_bb0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12886-021-02152-6","article-title":"Aqueous humor cytokine levels through microarray analysis and a sub-analysis based on optical coherence tomography in wet age-related macular degeneration patients","volume":"21","author":"Joo","year":"2021","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0115","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2147\/DDDT.S307657","article-title":"Cytokine and chemokine profile changes in patients with Neovascular age-related macular degeneration after intravitreal Ranibizumab injection for choroidal neovascularization","volume":"15","author":"Sun","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.cyto.2025.156921_bb0120","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.ophtha.2009.04.038","article-title":"Monitoring ocular drug therapy by analysis of aqueous samples","volume":"116","author":"Campochiaro","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cyto.2025.156921_bb0125","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/IAE.0b013e31818358b2","article-title":"Changes in aqueous vascular endothelial growth factor and pigment epitelial- derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age- related macular degeneration or pathologic myopia","volume":"28","author":"Chan","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.cyto.2025.156921_bb0130","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ajo.2009.06.012","article-title":"Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exuda- tive age-related macular degeneration","volume":"148","author":"Ahn","year":"2009","journal-title":"Am. J. Ophthalmol."},{"issue":"9","key":"10.1016\/j.cyto.2025.156921_bb0135","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/IAE.0b013e3181b32c45","article-title":"Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial","volume":"29","author":"Lai","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.cyto.2025.156921_bb0140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","volume":"141","author":"Tong","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0145","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0002-9394(02)01549-0","article-title":"Pigment epithelium-derived factor is defi- cient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration","volume":"134","author":"Holekamp","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.survophthal.2005.12.001","article-title":"The role of inflammation in the pathogenesis of age-related macular degeneration","volume":"51","author":"Donoso","year":"2006","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0155","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1167\/iovs.13-12730","article-title":"Comparative analysis of aqueous humor cytokine levels between patients with exudative age-related macular degeneration and normal controls","volume":"54","author":"Cha","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cyto.2025.156921_bb0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000365487","article-title":"Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration","volume":"53","author":"Sakurada","year":"2015","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.cyto.2025.156921_bb0165","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/02713683.2019.1614197","article-title":"The placental growth factor pathway and its potential role in macular degenerative disease","volume":"44","author":"Cunningham","year":"2019","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.cyto.2025.156921_bb0170","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.2147\/OPTH.S171636","article-title":"Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment","volume":"12","author":"Pongsachareonnont","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12974-019-1419-2","article-title":"Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina J neuroinflammation","volume":"16","author":"Balser","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.cyto.2025.156921_bb0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14728222.2022.2030706","article-title":"Disease progression pathways of wet AMD: opportunities for new target discovery","volume":"26","author":"Wolf","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.cyto.2025.156921_bb0185","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","article-title":"A randomized controlled trial of OPT-302, a VEGF-C\/D inhibitor for Neovascular age-related macular degeneration","volume":"130","author":"Jackson","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cyto.2025.156921_bb0190","doi-asserted-by":"crossref","unstructured":"Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am. J. Ophthalmol. 2005;139:537\u201340. doi: https:\/\/doi.org\/10.1016\/j.ajo.2004.09.058.","DOI":"10.1016\/j.ajo.2004.09.058"},{"key":"10.1016\/j.cyto.2025.156921_bb0195","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/jop.2012.0203","article-title":"Intravitreal tumor necrosis factor-alpha inhibitors for Neovascular age-related macular degeneration suboptimally responsive to Antivascular endothelial growth factor agents: a pilot study from the Pan American collaborative retina study group","volume":"29","author":"Wu","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.cyto.2025.156921_bb0200","doi-asserted-by":"crossref","first-page":"18084","DOI":"10.1038\/s41598-021-97522-x","article-title":"Macrophage-derived interleukin-6 is necessary and sufficient for choroidal angiogenesis","volume":"10","author":"Droho","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.156921_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.594087","article-title":"Molecular biomarkers of Neovascular age-related macular degeneration with incomplete response to anti-vascular endothelial growth factor treatment","volume":"11","author":"Mantel","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cyto.2025.156921_bb0210","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.7150\/thno.34681","article-title":"New CXCR1\/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments","volume":"9","author":"Dufies","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.cyto.2025.156921_bb0215","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.18240\/ijo.2020.07.04","article-title":"Blocking VEGF signaling augments interleukin-8 secretion via MEK\/ERK\/1\/2 axis in human retinal pigment epithelial cells","volume":"13","author":"Zhou","year":"2020","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ajo.2011.06.001","article-title":"Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study","volume":"143","author":"Dell\u2019Omo","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0225","first-page":"2654","article-title":"Neovascular morphology on ICG angiography predicts response to anti-VEGFA therapy in eyes with serous pigment epithelial detachments and age-related macular degeneration","volume":"53","author":"Mettu","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cyto.2025.156921_bb0230","first-page":"1758","article-title":"Characterisation of macular neovascularization subtypes in age-related macular degeneration to optimize treatment outcomes","volume":"37","author":"Mathis","year":"2023","journal-title":"Eye(Lond)."},{"key":"10.1016\/j.cyto.2025.156921_bb0235","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.86.4.448","article-title":"Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window","volume":"86","author":"Boyd","year":"2002","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156921_bb0240","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.eye.6702498","article-title":"Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion","volume":"22","author":"Noma","year":"2008","journal-title":"Eye"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625000687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625000687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:48:18Z","timestamp":1745326098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":48,"alternative-id":["S1043466625000687"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156921","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aqueous humor mediator levels as biomarkers of anti-VEGF response in age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"156921"}}